


AMENDMENTS TO THE CLAIMS

1. (Original) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a carbohydrate molecule having as an essential constituent an oligosaccharide chain represented by the following formula (I):




(wherein Hex¹ and Hex² represent a hexose).

2. (Original) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a molecule represented by the following formula (II):



(wherein X represents an oligosaccharide chain represented by the following formula (I):



(wherein Hex¹ and Hex² represent a hexose); R is a substrate selected from the group consisting of a hydrogen atom, a substituent having an S, N, O or P atom, a hydrocarbon group, a lipid, a protein and a synthetic polymer, each of which may have a substituent; n is a number of 1 or greater representing the number of the oligosaccharide chains binding to R).

3. (Original) The dengue virus infection inhibitor according to Claim 1 or 2, wherein either a hexose represented by Hex³ or an aminohexose represented by Hex³NAc is beta-1-4 linked to the non-reduced end of the oligosaccharide chain represented by the formula (I).

4. (Original) The dengue virus infection inhibitor according to Claim 1 or 2, wherein Hex¹ in the oligosaccharide chain represented by the formula (I) is glucose (Glc), and Hex² is galactose (Gal) or mannose (Man).

5. (Original) The dengue virus infection inhibitor according to Claim 3, wherein Hex¹ in the oligosaccharide chain represented by the formula (I) is glucose (Glc), Hex² is

galactose (Gal) or mannose (Man), and Hex³ is galactose (Gal) or N-acetyl galactosamine (GalNAc).

6. (Original) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is paragloboside represented by

Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc β 1- (Ia).

7. (Original) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is

Gal β 1-4GlcNAc β 1-3Man β 1-4Glc β 1- (Ib).

8. (Original) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is

GalNAc β 1-4GlcNAc β 1-3Gal β 1-4Glc β 1- (Ic).

9. (Cancelled)

10. (Original) A monoclonal antibody to an oligosaccharide chain represented by the following formula (Ib):

Gal β 1-4GlcNAc β 1-3Man β 1-4Glc β 1- (Ib).

11. (Original) A monoclonal antibody to an oligosaccharide chain represented by the following formula (Ic):

GalNAc β 1-4GlcNAc β 1-3Gal β 1-4Glc β 1- (Ic).

12. (Currently Amended) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a monoclonal antibody to any one of ~~Claims 9 to 11~~ of the oligosaccharide chains represented by the formulae (Ia) to (Ic):

Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc β 1- (Ia);

Gal β 1-4GlcNAc β 1-3Man β 1-4Glc β 1- (Ib);

GalNAc β 1-4GlcNAc β 1-3Gal β 1-4Glc β 1- (Ic).

13. (New) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is

GlcNAc β 1-3Man β 1-4Glc β 1-1Cer (Id).

14. (New) A monoclonal antibody to an oligosaccharide chain represented by the following formula (Id):

GlcNAc β 1-3Man β 1-4Glc β 1-1Cer (Id).

15. (New) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a monoclonal antibody to the oligosaccharide chain represented by the formulae (Id):

GlcNAc β 1-3Man β 1-4Glc β 1-1Cer (Id).

16. (New) An oligosaccharide chain represented by the following formula (Ie):

Gal β 1-4GlcNAc β 1-3Man β 1-4Glc β 1-1Cer (Ie).

17. (New) The dengue virus infection inhibitor according to Claim 3, wherein the oligosaccharide chain represented by the formula (I) is

Gal β 1-4GlcNAc β 1-3Man β 1-4Glc β 1-1Cer (Ie).

18. (New) A monoclonal antibody to an oligosaccharide chain represented by the following formula (Ie):

Gal β 1-4GlcNAc β 1-3Man β 1-4Glc β 1-1Cer (Ie).

19. (New) A dengue virus infection inhibitor characterized by containing, as the active ingredient, at least a monoclonal antibody to the oligosaccharide chain represented by the formulae (Ie):

Gal β 1-4GlcNAc β 1-3Man β 1-4Glc β 1-1Cer (Ie).